Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2020 September;64(3) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2020 September;64(3):291-8

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

ORIGINAL ARTICLE   

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2020 September;64(3):291-8

DOI: 10.23736/S1824-4785.19.03140-6

Copyright © 2019 EDIZIONI MINERVA MEDICA

lingua: Inglese

Is 18F-fluorodeoxyglucose positron emission tomography/computed tomography useful to discriminate metachronous lung cancer from metastasis in patients with oncological history?

Silvia TARALLI 1, Valentina SCOLOZZI 1, 2, Elizabeth K. TRIUMBARI 1, 2, Francesco CARLEO 3, Marco DI MARTINO 3, Alessia R. DE MASSIMI 3, Sara RICCIARDI 4, Giuseppe CARDILLO 3, Maria L. CALCAGNI 1, 2

1 UOC di Medicina Nucleare, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; 2 Istituto di Medicina Nucleare, Università Cattolica del Sacro Cuore, Rome, Italy; 3 Unit of Thoracic Surgery, San Camillo Forlanini Hospital, Rome, Italy; 4 Unit of Thoracic Surgery, University Hospital of Pisa, Pisa, Italy



BACKGROUND: Solitary pulmonary nodules detected during follow-up in patients with previous cancer history have a high probability of malignancy being either a metachronous lung cancer or a metastasis. This distinction represents a crucial issue in the perspective of “personalized medicine,” implying different treatments and prognosis. Aim: to evaluate the role of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) in distinguishing whether solitary pulmonary nodules are metachronous cancers or metastases and the relationship between the nodule’s characteristics and their nature.
METHODS: From a single-institution database, we retrospectively selected all patients with a previous cancer history who performed 18F-FDG PET/CT to evaluate pulmonary nodules detected during follow-up, ranging from 5 mm to 40 mm, and histologically diagnosed as malignant.
RESULTS: Between September 2009 and August 2017, 127 patients (80 males; mean age=70.2±8.5years) with 127 malignant nodules were included: 103/127 (81%) metachronous cancers, 24/127 (19%) metastases. In both groups, PET/CT provided good and equivalent detection rate of malignancy (81% vs. 83%). No differences between metachronous cancers and metastases were found in: patient’s age (70.3±8.1 years vs. 69.5±9.7years), gender (males=63.1% vs. 62.5%), interval between previous cancer diagnosis and nodules’ detection (median time=4years vs. 4.5years), location (right-lung=55% vs. 54%; upper-lobes=64% vs. 67%; central-site=31% vs. 25%), size (median size=17mm vs. 19.5mm), 18F-FDG standardized uptake value (median SUVmax=5.2 vs. 5.9).
CONCLUSIONS: In oncological patients, despite its high detection rate, 18F-FDG PET/CT, as well as any other clinico-anatomical features, cannot distinguish whether a malignant solitary pulmonary nodule is a metachronous lung cancer or a metastasis, supporting the need of histological differential diagnosis.


KEY WORDS: Solitary pulmonary nodule; Fluorodeoxyglucose F18; Positron emission tomography computed tomography; Neoplasm metastasis

inizio pagina